Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX

Key Points

• Walleye Capital acquired 245,587 Kyverna Therapeutics shares worth approximately $2.19 million, giving it a 0.40% stake. Institutional investors and hedge funds collectively own 18.08% of KYTX.
• Kyverna reported a quarterly loss of $0.63 per share, beating the expected $0.68 loss, but analysts still forecast a full-year loss of approximately $2.70 per share. The stock opened at $8.17 and remains highly volatile, with a beta of 1.93.
• Analyst views are mixed, though the consensus remains a “Moderate Buy” with a $30 price target. Kyverna’s investment case depends on progress in clinical and regulatory development of its engineered T-cell therapies, while ongoing losses and financing needs remain key risks.

Walleye Capital LLC purchased a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 245,587 shares of the company's stock, valued at approximately $2,188,000. Walleye Capital LLC owned 0.40% of Kyverna Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in KYTX. Adage Capital Partners GP L.L.C. purchased a new position in Kyverna Therapeutics in the 4th quarter valued at about $15,667,000. AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics during the fourth quarter worth about $14,100,000. Balyasny Asset Management L.P. purchased a new stake in shares of Kyverna Therapeutics during the fourth quarter worth about $9,220,000. Propel Bio Management LLC purchased a new stake in shares of Kyverna Therapeutics during the fourth quarter worth about $6,267,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Kyverna Therapeutics in the fourth quarter worth about $5,640,000. Institutional investors and hedge funds own 18.08% of the company's stock.

Kyverna Therapeutics Stock Performance

KYTX stock opened at $8.17 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.15 and a current ratio of 9.06. The stock has a market capitalization of $505.26 million, a price-to-earnings ratio of -2.78 and a beta of 1.93. Kyverna Therapeutics, Inc. has a 1 year low of $3.27 and a 1 year high of $13.67. The stock's fifty day moving average is $8.07 and its two-hundred day moving average is $8.43.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.05. On average, research analysts predict that Kyverna Therapeutics, Inc. will post -2.7 EPS for the current year.

Analysts Set New Price Targets

KYTX has been the subject of several research analyst reports. Wall Street Zen cut Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. JPMorgan Chase & Co. lowered their price objective on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an "overweight" rating for the company in a research report on Wednesday, May 13th. HC Wainwright reiterated a "buy" rating and set a $25.00 price objective on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Kyverna Therapeutics in a report on Wednesday, June 24th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $30.00.

Kyverna Therapeutics News Roundup

Here are the key news stories impacting Kyverna Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its estimates across multiple periods, including FY2026 EPS to a loss of $2.70 from $2.98 and FY2027 EPS to a loss of $2.79 from $3.01. The firm maintained a Buy rating and a $25 price target, implying substantial upside from recent trading levels. MarketBeat Kyverna Therapeutics analyst estimates
• Positive Sentiment: The revised forecasts also improved expected quarterly results for Q3 and Q4 2026 and Q1 through Q4 2027, suggesting HC Wainwright sees a better earnings trajectory, although KYTX is still expected to remain unprofitable. The company recently beat quarterly EPS expectations, reporting a $0.63 loss versus the $0.68 consensus loss.
• Positive Sentiment: Kyverna’s reported progress toward potential approval supports the long-term investment case because successful regulatory advancement could improve the prospects for its cell-therapy platform. Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval
• Neutral Sentiment: Despite the favorable HC Wainwright view, broader analyst opinions on KYTX remain mixed. That lack of consensus likely limited the stock’s reaction to the improved estimates and approval-related progress. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: Kyverna remains a development-stage biotechnology company with substantial expected losses, making the stock highly dependent on clinical, regulatory and financing progress. Its beta of 1.93 also indicates elevated volatility.

Kyverna Therapeutics Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source